Blood Testing Companies’ Earnings Diverge; Natera’s Loss Exceeds Expectations

According to TechFlow, on November 6, as reported by Investor's Business Daily, blood testing companies Natera and Guardant Health reported third-quarter earnings, and both raised full-year revenue guidance. Previously, weak sales of peer Grail’s cancer detection product Galleri disappointed investors.

Natera reported a loss per share of $0.42, worse than the market expectation of $0.29; revenue was $794 million, above the expected $708 million. Guardant Health reported a loss per share of $0.29, smaller than the expected $0.31; revenue was $361 million, above the expected $351 million.

The report also noted that cancer tissue testing company Veracyte saw weak prostate cancer testing volume; laboratory research tools company 10x Genomics reported a third-quarter loss per share of $0.15 and revenue of $150.7 million, both better than market expectations.

Source: TechFlow